Description
An irreversible inhibitor of BTK (IC50 = 0.5 nM) that selectively blocks B cell activation, promoting apoptosis and preventing homing to the protective tumor microenvironment, at concentrations that do not affect T cell receptor signaling (1,000-fold more potent); studied clinically for the treatment of diseases associated with B cell antigen receptor signaling, including MCL, CLL, and non-Hodgkin
Formal name: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one
Synonyms: Imbruvica|PCI 32765
Molecular weight: 440.5
CAS: 936563-96-1
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|Tec Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Tec Family Signaling||Research Area|Cancer|Tumor Microenvironment||Research Area|Immunology & Inflammation|Adaptive Immunity